» UTSA Expressions -- Student Center for Community Engagement and Inclusion
» Discovery -- UTSA Research
» Innovations -- College of Engineering
» Ovations -- College of Liberal and Fine Arts
» Spectrum -- College of Education
UTSA, InCube Labs sign five-year master sponsored research agreement
By Christi Fish
Associate Director of Media Relations
(Oct. 26, 2012) -- The University of Texas at San Antonio and San Antonio-based InCube Labs have signed a five-year master sponsored research agreement that will guide the organizations in jointly developing biomedical technologies and devices to solve some of today's key unmet clinical needs.
The agreement outlines how UTSA and InCube will jointly develop research programs aligned with the mission of both organizations. Generally, UTSA will provide scholars, students and facilities to conduct the research. Mir Imran, chairman and CEO of InCube Labs, and his team will provide the strategic guidance and leadership to develop technologies, conduct clinical trials and assist in the early stages of commercialization.
The agreement addresses how the two organizations will collaborate including how they will approach research reporting, publications, publicity, confidentiality, intellectual property rights, liability and independent contractors.
"UTSA exists to educate students so they are prepared for jobs in the global workforce and to add to the body of knowledge in our areas of expertise. This partnership with InCube will allow us to do both," said Cory Hallam, chief commercialization officer and director of the UTSA Center for Innovation and Technology Entrepreneurship. "Working with InCube gives our students the opportunity to conduct sophisticated research in biomedical technology development while contributing new insights that will advance the field."
InCube Labs opened a branch of its operations in San Antonio in 2010 to continue its commitment to develop and commercialize medical innovations such as new implantable devices, drug delivery combinations, interventional devices and novel biomaterials. Representing InCube's first geographic expansion since its founding in Silicon Valley in 1995, InCube Lab's San Antonio Innovation Center includes InCube Labs as well as three of its medical technology companies, Corhythm, Neurolink and Fe3 Medical.
"We're looking forward to collaborating with UTSA, and tapping into its wealth of talented researchers and resources, to develop breakthrough technologies that have the potential to dramatically improve the standard of care for patients," said Phil Morgan, general manager and vice president for InCube Labs San Antonio. "This five year agreement creates the framework for a mutually beneficial and highly productive collaboration that helps move promising innovations down the commercialization path and into the market."
"We are extremely pleased to strengthen our relationship with InCube through this agreement and look forward to additional projects with them," said James Casey, UTSA assistant vice president for sponsored project administration, whose office negotiated the agreement.
UTSA was founded in 1969 and has grown to enroll nearly 31,000 students in more than 130 degree programs. The university specializes in health, energy, security, sustainability, and human and social development research.
About InCube Labs
Based in Silicon Valley and San Antonio, InCube Labs is a life sciences research lab focused on developing medical breakthroughs that dramatically improve patient outcomes. Their multi-disciplinary approach integrates traditional device technologies such as electronics, software, mechanical engineering and material science with innovations from the pharmaceutical industry involving protein chemistry, pharmacology and cell biology.
InCube is led by Mir Imran, an accomplished medical innovator, entrepreneur and venture capitalist, who has founded more than 20 life sciences companies and holds more than 200 patents. Many of Imran's innovations have resulted in new standards of care including the first FDA-approved automatic implantable cardioverter defibrillator.